Brought to you by 
Glaxo gets global rights to MorphoSys’ rheumatoid arthritis antibody MOR103
03 Mar 2021
Executive Summary
MorphoSys AG (fully human antibody technologies) has granted GlaxoSmithKline PLC worldwide rights to its lead candidate MOR103, in Phase I/II for mild-to-moderate rheumatoid arthritis, and in Phase I for multiple sclerosis. MOR103 was renamed otilimab (GSK3196165).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo gets global rights to MorphoSys’ rheumatoid arthritis antibody MOR103
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice